AKT1 and renal cell carcinoma: Thus, we may assume that PTEN has not yet suffered a loss; so, in addition to preserving its tumor suppressor function, we may assume that in the studied samples lower or higher PTEN expression, as a key regulator of the PI3K/AKT pathway, may influence the prognosis of RCC, disease outcomes, and therapeutic strategies [57,58].